CA2861307C - High affinity sirp-alpha reagents - Google Patents

High affinity sirp-alpha reagents Download PDF

Info

Publication number
CA2861307C
CA2861307C CA2861307A CA2861307A CA2861307C CA 2861307 C CA2861307 C CA 2861307C CA 2861307 A CA2861307 A CA 2861307A CA 2861307 A CA2861307 A CA 2861307A CA 2861307 C CA2861307 C CA 2861307C
Authority
CA
Canada
Prior art keywords
sirpa
high affinity
polypeptide variant
substitutions
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2861307A
Other languages
English (en)
French (fr)
Other versions
CA2861307A1 (en
Inventor
Aaron Michael RING
Kenan Christopher GARCIA
Kipp Andrew WEISKOPF
Aron M. Levin
Irving L. Weissman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CA2861307A1 publication Critical patent/CA2861307A1/en
Application granted granted Critical
Publication of CA2861307C publication Critical patent/CA2861307C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2861307A 2012-01-17 2013-01-17 High affinity sirp-alpha reagents Active CA2861307C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261587247P 2012-01-17 2012-01-17
US61/587,247 2012-01-17
PCT/US2013/021937 WO2013109752A1 (en) 2012-01-17 2013-01-17 High affinity sirp-alpha reagents

Publications (2)

Publication Number Publication Date
CA2861307A1 CA2861307A1 (en) 2013-07-25
CA2861307C true CA2861307C (en) 2021-05-25

Family

ID=48799653

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2861307A Active CA2861307C (en) 2012-01-17 2013-01-17 High affinity sirp-alpha reagents

Country Status (19)

Country Link
US (4) US9944911B2 (https=)
EP (2) EP3766511A1 (https=)
JP (5) JP6460796B2 (https=)
CN (2) CN107880100A (https=)
AU (1) AU2013209736C1 (https=)
CA (1) CA2861307C (https=)
CY (1) CY1123419T1 (https=)
DK (1) DK2804617T3 (https=)
ES (1) ES2816647T3 (https=)
HK (1) HK1253217A1 (https=)
HR (1) HRP20201285T1 (https=)
HU (1) HUE050875T2 (https=)
LT (1) LT2804617T (https=)
PL (1) PL2804617T3 (https=)
PT (1) PT2804617T (https=)
RS (1) RS60606B1 (https=)
SI (1) SI2804617T1 (https=)
SM (1) SMT202000689T1 (https=)
WO (1) WO2013109752A1 (https=)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2816647T3 (es) * 2012-01-17 2021-04-05 Univ Leland Stanford Junior Reactivos SIRP-alfa de alta afinidad
KR102100388B1 (ko) 2012-02-06 2020-04-13 인히브릭스, 인크. Cd47 항체 및 그 사용 방법
PL3575326T3 (pl) * 2012-12-17 2022-07-11 Pf Argentum Ip Holdings Llc Leczenie komórek chorobowych cd47+ z użyciem fuzji sirp alfa-fc
CN112245586A (zh) * 2013-03-15 2021-01-22 小利兰·斯坦福大学托管委员会 用于实现治疗有效剂量的抗cd47剂的方法
JP6843611B2 (ja) 2013-04-29 2021-03-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 免疫を強化する抗ｃｄ４７因子の使用
EP3046627B1 (en) * 2013-09-18 2019-10-23 The Board of Trustees of the Leland Stanford Junior University Modulation of efferocytosis pathways for treatment of atherosclerotic disease
ES2811274T3 (es) 2014-04-18 2021-03-11 Univ Leland Stanford Junior Anticuerpos monoclonales humanizados y quiméricos para CD99
PT3177640T (pt) 2014-08-08 2020-08-31 Univ Leland Stanford Junior Agentes pd-1 de alta afinidade e métodos de utilização
WO2016022971A1 (en) 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Sirp alpha-antibody fusion proteins
WO2016023040A1 (en) * 2014-08-08 2016-02-11 Alexo Therapeutics International Sirp-alpha variant constructs and uses thereof
WO2016023001A1 (en) * 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Multispecific high affinity pd-1 agents and methods of use
PL3180363T3 (pl) 2014-08-15 2020-02-28 Merck Patent Gmbh Białka fuzyjne immunoglobulin sirp-alfa
EP4257145B1 (en) 2014-08-26 2025-06-25 The Board of Trustees of the Leland Stanford Junior University Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling
US10822411B2 (en) 2014-09-15 2020-11-03 The Board Of Trustees Of The Leland Stanford Junior University Targeting aneurysm disease by modulating phagocytosis pathways
EP3012271A1 (en) 2014-10-24 2016-04-27 Effimune Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
CA2959821C (en) 2014-10-24 2024-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of MHC class I positive cells and for overcoming resistance to anti-CD47 agents/SIRPA
EP3221358B1 (en) * 2014-11-18 2021-07-21 Janssen Pharmaceutica, N.V. Cd47 antibodies, methods, and uses
MX391051B (es) * 2014-12-30 2025-03-21 Celgene Corp Anticuerpos anti-cd47 y usos de los mismos.
WO2016138306A1 (en) 2015-02-27 2016-09-01 The Board Of Trustees Of The Leland Stanford Junior University Combination therapy for treatment of coronary artery disease
CN106146670B (zh) * 2015-04-24 2019-01-15 宜明昂科生物医药技术（上海）有限公司 一种新的重组双功能融合蛋白及其制备和应用
US10358472B2 (en) 2015-05-06 2019-07-23 The Board Of Trustees Of The Leland Stanford Junior University High affinity CD47 analogs
CN114425077A (zh) * 2015-05-18 2022-05-03 起源生物医药公司 Sirp多肽组合物和使用方法
AU2016304794B2 (en) * 2015-08-07 2021-07-15 ALX Oncology Inc. Constructs having a SIRP-alpha domain or variant thereof
EA034582B1 (ru) * 2015-08-07 2020-02-21 АЭлЭкс ОНКОЛОДЖИ ИНК. Конструкции варианта sirp-альфа и их применение
AU2016310348B2 (en) 2015-08-26 2023-01-05 The Board Of Trustees Of The Leland Stanford Junior University Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist
CN108367073A (zh) * 2015-12-11 2018-08-03 小利兰·斯坦福大学托管委员会 以双重靶向cd47和egfr来治疗癌症
PT3402820T (pt) 2016-01-11 2020-08-20 Forty Seven Inc Anticorpos monoclonais anti-cd47 quiméricos, de ratinho ou humanizados
IL262251B2 (en) 2016-04-14 2023-09-01 Ose Immunotherapeutics New anti-syrap antibodies and their medical applications
KR102505253B1 (ko) 2016-04-15 2023-03-02 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법
WO2017184553A1 (en) * 2016-04-18 2017-10-26 Baylor College Of Medicine Cancer gene therapy targeting cd47
JP7160683B2 (ja) * 2016-04-29 2022-10-25 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 術後癒着の予防及び治療のための方法及び組成物
US11560433B2 (en) 2016-05-27 2023-01-24 Albert Einstein College Of Medicine Methods of treatment by targeting VCAM1 and MAEA
US10277886B2 (en) 2016-07-19 2019-04-30 Gopro, Inc. Mapping of spherical image data into rectangular faces for transport and decoding across networks
EP3532497B1 (en) * 2016-10-26 2024-07-24 The Board of Trustees of the Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
CA3042581A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Enhancement of cd47 blockade therapy by proteasome inhibitors
CA3042583A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by hdac inhibitors
CN110248645B (zh) * 2016-12-29 2022-04-26 韩国科学技术研究院 基于外来体的抗癌剂
CN110536693B (zh) 2017-01-05 2023-12-22 卡尔医学有限公司 Pd1-41bbl融合蛋白及使用其的方法
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
RU2769769C2 (ru) 2017-01-05 2022-04-05 Кахр Медикал Лтд. СЛИТЫЙ БЕЛОК SIRPα-4-1BBL И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ
BR112019013863A2 (pt) 2017-01-06 2020-03-03 Synlogic Operating Company, Inc. Micro-organismos programados para produzir moduladores imunes e terapêuticos anticâncer em células tumorais
KR20190109440A (ko) 2017-01-30 2019-09-25 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 줄기 세포 이식을 위한 비-유전독성 컨디셔닝 레지멘
WO2018160739A1 (en) 2017-02-28 2018-09-07 The Board Of Trustees Of The Leland Stanford Junior University Antifibrotic activity of cd47 blockade
WO2018165015A1 (en) 2017-03-09 2018-09-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of cd47 pathway
WO2018237168A1 (en) 2017-06-21 2018-12-27 The Board Of Trustees Of The Leland Stanford Junior University Dosing parameters for cd47 targeting therapies to hematologic malignancies
JP2020527025A (ja) 2017-07-12 2020-09-03 シンロジック オペレーティング カンパニー インコーポレイテッド 腫瘍細胞において免疫モジュレーターおよび抗がん治療剤を産生するようにプログラムされた微生物
JP7262440B2 (ja) 2017-08-02 2023-04-21 フェインズ セラピューティクス，インコーポレーテッド 抗ｃｄ４７抗体及びその使用
CN111051350B (zh) * 2017-09-07 2022-11-01 苏州丁孚靶点生物技术有限公司 包含信号调节蛋白α的免疫缀合物
WO2019061012A1 (zh) * 2017-09-26 2019-04-04 南京凯地生物科技有限公司 靶向cd47的特异性嵌合抗原受体t细胞的制备及其应用
EP3694881A1 (en) 2017-10-13 2020-08-19 OSE Immunotherapeutics Modified anti-sirpa antibodies and uses thereof
JP7308191B2 (ja) 2017-10-18 2023-07-13 フォーティ セブン， インコーポレイテッド 抗ｃｄ４７剤ベースの卵巣癌療法
US11771764B2 (en) 2017-11-06 2023-10-03 Pfizer Inc. CD47 blockade with radiation therapy
SG11202004864TA (en) * 2017-12-01 2020-06-29 Seattle Genetics Inc Cd47 antibodies and uses thereof for treating cancer
EP3722312A4 (en) * 2017-12-08 2021-07-21 Hanx Biopharmaceutics, Inc BISPECIFIC ANTI-PD-1 / CD47 ANTIBODIES AND ASSOCIATED APPLICATION
CN109971716B (zh) * 2017-12-28 2023-08-01 上海细胞治疗研究院 自分泌cd47抗体的egfr特异性car-t细胞及其用途
CN111699005A (zh) 2018-02-12 2020-09-22 四十七公司 使用抗cd47抗体和抗cd20抗体的抗癌方案
CN108484774B (zh) * 2018-03-09 2021-11-05 上海高菲生物科技有限公司 一种SIRPα融合蛋白及其制备方法和用途
JP2021517130A (ja) 2018-03-13 2021-07-15 オーセ イミュノセラピューティクスＯｓｅ Ｉｍｍｕｎｏｔｈｅｒａｐｅｕｔｉｃｓ 抗ヒトＳＩＲＰａｖ１抗体の使用および抗ｖ１抗体を製造する方法
US20210040219A1 (en) * 2018-03-13 2021-02-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by egfr antibody
CN108872569A (zh) * 2018-06-19 2018-11-23 浠思（上海）生物技术有限公司 利用HTRF一步法筛选CD47/SIRP alpha阻断剂的方法
SG11202012338QA (en) 2018-07-10 2021-01-28 Univ Kobe Nat Univ Corp ANTI-SIRPa ANTIBODY
EP3820887A4 (en) 2018-07-11 2022-04-20 KAHR Medical Ltd. Pd1-4-1bbl variant fusion protein and methods of use thereof
KR102945860B1 (ko) 2018-07-11 2026-03-31 카 메디컬 리미티드 SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법
KR102129522B1 (ko) * 2018-07-26 2020-07-02 한국과학기술연구원 암세포 특이적 항암 단백질-형광 복합체 및 이를 포함하는 암의 진단 및 영상화용 조성물
US20210347848A1 (en) 2018-08-31 2021-11-11 ALX Oncology Inc. Decoy polypeptides
ES3007236T3 (en) 2018-09-04 2025-03-19 Pfizer Cd47 blockade with parp inhibition for disease treatment
CN109306017B (zh) * 2018-10-12 2021-02-09 倍而达药业（苏州）有限公司 一种基于SIRP-αD1突变体制备的重组蛋白及应用
WO2020095922A1 (ja) * 2018-11-07 2020-05-14 第一三共株式会社 ペプチドの血中動態改善方法
CN111303293B (zh) 2018-11-14 2022-08-30 杭州尚健生物技术有限公司 一种融合蛋白及其用途
EP3886869A4 (en) 2018-11-28 2022-07-06 Forty Seven, Inc. GENETICALLY MODIFIED ABLATION-RESISTANT HSPCS
WO2020107115A1 (en) * 2018-11-29 2020-06-04 Trillium Therapeutics Inc. Biomarkers for cd47 blockade therapy
MX2021007274A (es) 2018-12-21 2021-07-15 Ose Immunotherapeutics Molecula bifuncional anti-pd-1/sirpa.
CN113906140B (zh) 2019-03-18 2025-01-28 路德维格癌症研究院 A2/ny-eso-1特异性t细胞受体及其用途
CN114126648A (zh) 2019-05-31 2022-03-01 Alx肿瘤生物技术公司 用SIRPα Fc融合体组合免疫检查点抑制剂治疗癌症的方法
US20200400662A1 (en) 2019-06-07 2020-12-24 ALX Oncology Inc. Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
WO2020257196A1 (en) * 2019-06-17 2020-12-24 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating infections by blocking pathogen mimics of cd47
KR20240137107A (ko) 2019-07-16 2024-09-19 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
ES2973832T3 (es) 2019-10-18 2024-06-24 Forty Seven Inc Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda
JP2022552748A (ja) 2019-10-31 2022-12-19 フォーティ セブン， インコーポレイテッド 抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療
CN121243368A (zh) 2019-11-27 2026-01-02 Alx肿瘤生物技术公司 用于治疗癌症的组合疗法
IL294032A (en) 2019-12-24 2022-08-01 Carna Biosciences Inc Compounds that regulate diacylglycerol kinase
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
CN115916963A (zh) 2020-03-27 2023-04-04 门德斯有限公司 白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途
CN115803092A (zh) * 2020-04-24 2023-03-14 乔治亚州立大学研究基金公司 用于治疗癌症的缺乏SIRPα的巨噬细胞
KR20230018475A (ko) 2020-06-01 2023-02-07 알렉소 온콜로지 인크. 암 치료용 저메틸화제를 포함하는 병용 요법
EP4171617A1 (en) 2020-06-30 2023-05-03 Mendus B.V. Use of leukemia-derived cells in ovarian cancer vaccines
WO2022010806A1 (en) 2020-07-06 2022-01-13 ALX Oncology Inc. Methods for reducing the interference of drugs that bind therapeutic targets expressed on blood cells in serological assays
CN114057888A (zh) * 2020-07-30 2022-02-18 三生国健药业（上海）股份有限公司 一种SIRPα-Fc融合蛋白
JP7446953B2 (ja) * 2020-08-27 2024-03-11 株式会社三共 遊技機
KR102557016B1 (ko) * 2020-09-22 2023-07-20 비피진 주식회사 암 치료를 위한 cd47 바인더 및 리포좀 복합체
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
KR20230114748A (ko) * 2020-10-28 2023-08-01 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 혈관 염증 감소를 위한 cd47 차단 및 이의 조합 요법
US20220196651A1 (en) * 2020-12-06 2022-06-23 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
CA3212351A1 (en) 2021-03-12 2022-09-15 Mendus B.V. Methods of vaccination and use of cd47 blockade
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
JP2024515211A (ja) 2021-04-27 2024-04-05 ファイザー・インク Ｄｈｆｒ阻害剤を用いたｃｄ４７遮断療法の増強
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
JP7686091B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
AU2022299051B2 (en) 2021-06-23 2025-03-13 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
KR20230016152A (ko) * 2021-07-19 2023-02-01 주식회사유한양행 Sirp-alpha 변이체 및 이의 용도
AU2022375782B2 (en) 2021-10-28 2026-02-26 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
JP7787991B2 (ja) 2021-10-29 2025-12-17 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３化合物
US20250235504A1 (en) 2021-10-29 2025-07-24 Pfizer Inc. Enhancement of cd47 blockade with taxanes for cd47+ cancer therapy
WO2023072279A1 (zh) * 2021-11-01 2023-05-04 江苏先声药业有限公司 SIRPa突变体及其应用
US20250367255A1 (en) 2021-11-08 2025-12-04 Pfizer Inc. Enhancement Of CD47 Blockade Therapy With Anti-VEGF Agents
WO2023107956A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
US20230220106A1 (en) 2021-12-08 2023-07-13 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
KR20250172692A (ko) * 2021-12-21 2025-12-09 에프비디 바이올로직스 리미티드 조작된 SIRPα 변이체 및 이의 사용 방법
US12122764B2 (en) 2021-12-22 2024-10-22 Gilead Sciences, Inc. IKAROS zinc finger family degraders and uses thereof
KR20240123836A (ko) 2021-12-22 2024-08-14 길리애드 사이언시즈, 인코포레이티드 이카로스 아연 핑거 패밀리 분해제 및 이의 용도
CN118401559A (zh) * 2021-12-23 2024-07-26 Fbd生物制品有限公司 靶向cd47/4-1bb的蛋白质复合物和其使用方法
CN118401564A (zh) * 2022-01-18 2024-07-26 Fbd生物制品有限公司 靶向cd47/pd-l1的蛋白质复合物和其使用方法
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
US20250302953A1 (en) 2022-02-14 2025-10-02 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
WO2023178181A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
IL315706A (en) 2022-03-24 2024-11-01 Bitterroot Bio Inc Sirp-alpha fusion polypeptides with modified fc domains
US20250257113A1 (en) * 2022-03-24 2025-08-14 The Board Of Trustees Of The Leland Stanford Junior University Multivalent sirp-alpha fusion polypeptides
KR20240165995A (ko) 2022-03-24 2024-11-25 길리애드 사이언시즈, 인코포레이티드 Trop-2 발현 암의 치료를 위한 병용요법
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
CR20240451A (es) 2022-04-21 2024-12-04 Gilead Sciences Inc Compuestos de modulación de kras g12d
EP4519283A4 (en) * 2022-05-06 2025-10-01 Biosion Inc RECOMBINANT FUSION PROTEIN TARGETING CD40 AND CD47
US20250345395A1 (en) 2022-05-25 2025-11-13 Pfizer Inc. Dosing Regimens of SIRP Alpha Fusion Proteins for Treatment of Cancer
US20240010701A1 (en) 2022-06-01 2024-01-11 ALX Oncology Inc. Combination therapies for treating urothelial carcinoma
KR20250028371A (ko) 2022-07-01 2025-02-28 길리애드 사이언시즈, 인코포레이티드 Cd73 화합물
CA3259040A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. HIV Immunogenic Polypeptides and Vaccines and Their Uses
WO2024015634A2 (en) * 2022-07-15 2024-01-18 Nutcracker Therapeutics, Inc. Mrna therapies including sirp-alpha
WO2024040151A1 (en) 2022-08-18 2024-02-22 Pfizer Inc. Sirp alpha fusion protein and anti-cd38 antibody combination therapies
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
KR20250116736A (ko) 2022-12-09 2025-08-01 화이자 인코포레이티드 Cd47 차단제 및 항-bcma/항-cd3 이중특이성 항체 병용 요법
WO2024124107A2 (en) 2022-12-09 2024-06-13 Pfizer Inc. Cd47 blocking agent and anti-cd20 / anti-cd3 bispecific antibody combination therapy
AU2023409398A1 (en) 2022-12-22 2025-06-05 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN121240869A (zh) * 2023-03-22 2025-12-30 李望智 Sirp变体及其用途
AU2024252725A1 (en) 2023-04-11 2025-11-06 Gilead Sciences, Inc. Kras modulating compounds
CR20250446A (es) 2023-04-21 2025-12-02 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
EP4490201A4 (en) 2023-05-31 2026-03-11 Fbd Biologics Ltd CD47/PD-L1 Targeted Protein Complex and Its Methods of Use
TW202511298A (zh) * 2023-05-31 2025-03-16 香港商Ｆｂｄ生物製劑有限公司 靶向ｃｄ４７／ｐｄ—ｌ１之蛋白質複合物及其使用方法
AU2024306338A1 (en) 2023-06-30 2026-01-08 Gilead Sciences, Inc. Kras modulating compounds
KR20260046403A (ko) 2023-07-26 2026-04-07 길리애드 사이언시즈, 인코포레이티드 Parp7 저해제
CN121620513A (zh) 2023-07-26 2026-03-06 吉利德科学公司 Parp7抑制剂
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025247303A1 (zh) * 2024-05-30 2025-12-04 上海艾乐晞生物科技有限公司 具有pH依赖结合活性的人信号调节蛋白α突变体及其应用
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds
WO2026062544A1 (en) 2024-09-23 2026-03-26 Pfizer Inc. Sirp alpha fusion protein formulation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541615B1 (en) * 1996-11-15 2003-04-01 Max-Planck-Gellschaft Zur Foderung Der Wissenschaften E.V. SIRP proteins and uses thereof
EP1192176A4 (en) * 1999-06-11 2003-03-05 Human Genome Sciences Inc 49 HUMAN SECRETED PROTEINS
AU2003264100A1 (en) * 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of a bilin-binding protein with affinity for a given target
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
EP2573112A1 (en) 2007-10-11 2013-03-27 The Hospital For Sick Children Modulation of sirpa - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
WO2010070047A1 (en) * 2008-12-19 2010-06-24 Novartis Ag Soluble polypeptides for use in treating autoimmune and inflammatory disorders
HRP20150553T1 (hr) * 2009-05-15 2015-08-28 University Health Network Sastavi i metode za lijeäśenje hematoloških maligniteta ciljajuä†i sirp - cd47 interakciju
ES2816647T3 (es) * 2012-01-17 2021-04-05 Univ Leland Stanford Junior Reactivos SIRP-alfa de alta afinidad
EP4257145B1 (en) * 2014-08-26 2025-06-25 The Board of Trustees of the Leland Stanford Junior University Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling
AU2016310348B2 (en) * 2015-08-26 2023-01-05 The Board Of Trustees Of The Leland Stanford Junior University Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist
KR102024554B1 (ko) * 2018-02-26 2019-09-24 엘지전자 주식회사 유도 가열 장치 및 유도 가열 장치의 제어 방법

Also Published As

Publication number Publication date
JP2020007329A (ja) 2020-01-16
PL2804617T3 (pl) 2020-11-30
JP6742279B2 (ja) 2020-08-19
AU2013209736A1 (en) 2014-08-07
AU2013209736B2 (en) 2017-09-07
CA2861307A1 (en) 2013-07-25
SI2804617T1 (sl) 2020-10-30
US12195532B2 (en) 2025-01-14
JP2021176873A (ja) 2021-11-11
HRP20201285T1 (hr) 2020-11-13
US20220064293A1 (en) 2022-03-03
EP2804617A4 (en) 2015-11-25
US11208481B2 (en) 2021-12-28
PT2804617T (pt) 2020-09-10
US20180195054A1 (en) 2018-07-12
EP2804617A1 (en) 2014-11-26
US20250223355A1 (en) 2025-07-10
DK2804617T3 (da) 2020-08-10
LT2804617T (lt) 2020-09-10
WO2013109752A1 (en) 2013-07-25
CN104136037B (zh) 2018-02-23
JP6460796B2 (ja) 2019-01-30
JP2018021016A (ja) 2018-02-08
HUE050875T2 (hu) 2021-01-28
EP2804617B1 (en) 2020-06-24
JP2015504899A (ja) 2015-02-16
HK1253217A1 (zh) 2019-06-14
EP2804617B9 (en) 2021-04-07
JP2020143104A (ja) 2020-09-10
RS60606B1 (sr) 2020-08-31
ES2816647T3 (es) 2021-04-05
SMT202000689T1 (it) 2021-01-05
CN107880100A (zh) 2018-04-06
JP6783361B2 (ja) 2020-11-11
AU2013209736C1 (en) 2017-12-14
US20150071905A1 (en) 2015-03-12
JP6918179B2 (ja) 2021-08-11
CN104136037A (zh) 2014-11-05
CY1123419T1 (el) 2021-12-31
US9944911B2 (en) 2018-04-17
EP3766511A1 (en) 2021-01-20
HK1201757A1 (en) 2015-09-11

Similar Documents

Publication Publication Date Title
US12195532B2 (en) High affinity SIRP-alpha reagents and methods of using
US10358472B2 (en) High affinity CD47 analogs
US12459999B2 (en) Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
EA030147B1 (ru) Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
WO2016023001A1 (en) Multispecific high affinity pd-1 agents and methods of use
JP2018510613A (ja) 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）抗体およびその派生使用
US20200330591A1 (en) Treatment
HK40043038A (en) High affinity sirp-alpha reagents
HK1201757B (en) High affinity sirp-alpha reagents
EA042544B1 (ru) Расщепляемые матриксными металлопротеиназами и расщепляемые сериновыми протеиназами вещества и способы их использования

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180103

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241224

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241224

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241224

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251223

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251223